BenevolentAI

Overview

BenevolentAI combines AI and machine learning with science to decipher complex disease biology, generate novel insights and discover more effective medicines. Its computational R&D platform spans every step of the drug discovery process, powering an in-house pipeline of 25+ drug programs from early discovery towards clinical phases. With several successful collaborations with leading pharmaceutical organizations, BenevolentAI is the only AI-drug discovery company with a clinically validated approach, having discovered a leading repurposed drug candidate for COVID-19.

BenevolentAI is headquartered in London with a research facility in Cambridge (UK) and a further office in New York, with a team of over 300 scientists and technologists progressing its mission to reinvent drug discovery and advance life-changing drugs through to the clinic.

Ken Mulvany, Brent Gutekunst, Ivan Griffin and Michael Brennan founded Stratified Medicine in November 13, 2013 in London, United Kingdom. The company changed its name to BenevolentAI in Sepetember 2016. It has offices in Cambridge, Belgium and New York.

Interview with BenevolentAI CEO Jackie Hunter

Timeline

April 8, 2021

Data From Eli Lilly’s COV-BARRIER Trial Shows Baricitinib Reduced Deaths In Hospitalised COVID-19 Patients By 38%

February 11, 2021

BenevolentAI announces dosing of the first patient in its randomised first-in-human clinical trial of BEN-2293, a molecule designed and developed by BenevolentAI to treat Atopic Dermatitis.

January 27, 2021

BenevolentAI And AstraZeneca Achieve Collaboration Milestone With Novel AI-Generated Chronic Kidney Disease Target

November 20, 2020

FDA Grants Emergency Use Authorisation For Baricitinib In Hospitalised COVID-19 Patients Nine Months After Initial Hypothesis Was Published By BenevolentAI

April 10, 2020

Potential Treatment For COVID-19 Identified By BenevolentAI Enters Randomised Clinical Trial

September 17, 2019

BenevolentAI raises a $90,000,000 venture round from Temasek Holdings.

April 29, 2019

AstraZeneca Starts Artificial Intelligence Collaboration To Accelerate Drug Discovery

May 1, 2018

BenevolentAI Makes Joanna Shields New CEO

August 2015

BenevolentAI raises a $87,000,000 seed round from Lansdowne Partners, Lundbeck, Upsher-Smith Laboratories and Woodford Investment Management.

2013

BenevolentAI was founded by Brent Gutekunst, Ivan Griffin, Ken Mulvany and Michael Brennan.

Funding rounds

Patents

Further Resources

Title

Author

Link

Type

Date

#GBMDay: An AI-Enabled Approach to GBM Drug Discovery

https://youtu.be/ilL60MvXarw

Web

July 29, 2021

AI Uncovers a Potential Treatment for Covid-19 Patients

Tom Simonite

https://www.wired.com/story/ai-uncovers-potential-treatment-covid-19-patients/

Web

April 17, 2020

AI: The Next Revolution In Medicine?

https://youtu.be/GbdjerXkqfY

Web

January 23, 2019

AstraZeneca scores new goal on the pipeline front, adding its first AI-generated target to the portfolio

Max Gelman

https://endpts.com/astrazeneca-scores-new-goal-on-the-pipeline-front-adding-its-first-ai-generated-target-to-the-portfolio/

Web

January 27, 2021

BenevolentAI & AstraZeneca: Fusing AI and Drug Discovery Expertise to Find New Treatments for CKD

https://www.youtube.com/watch?v=UpqT1ux9lrI&t=9s

Web

April 8, 2021

News

Title

Author

Date

Publisher

Description

BenevolentAI: Data from Eli Lilly's COV-BARRIER trial shows baricitinib reduced deaths in hospitalised COVID-19 patients by 38%

BenevolentAI

April 8, 2021

www.prnewswire.com:443

The latest data published in Eli Lilly's Phase 3 randomised, double-blind, placebo-controlled study (COV-BARRIER) shows the largest clinical effect reported to...

BenevolentAI announces first patient dosed in its Atopic Dermatitis clinical trial

BenevolentAI

February 11, 2021

www.prnewswire.com:443

/PRNewswire/ -- BenevolentAI, a leader in the application of AI and machine learning in drug discovery and development, announced dosing of the first patient...

AstraZeneca, BenevolentAI home in on computer-generated target for chronic kidney disease drugs

Conor Hale

January 27, 2021

FierceBiotech

After launching a collaboration nearly two years ago to bring artificial intelligence to kidney drug design, AstraZeneca and BenevolentAI believe they've discovered a winner.

BenevolentAI and AstraZeneca achieve collaboration milestone with novel AI-generated chronic kidney disease target

BenevolentAI

January 27, 2021

www.prnewswire.com:443

/PRNewswire/ -- BenevolentAI today announced that the biopharmaceutical company AstraZeneca has selected a novel chronic kidney disease (CKD) target to advance...

How AI could transform post-pandemic healthcare - Business Insider

Chris Stokel Walker

January 25, 2021

Business Insider

Because of her work, Insider named Joanna Shields, CEO of BenevolentAI, to our annual list of the 10 leaders transforming healthcare in Europe.